Von der Idee zur Wirklichkeit.
Das Schweizer Pharmaunternehmen InnoMedica definiert sich abgesehen von der eigenen patentgeschützten Technologieplattform vor allem über den Willen des Teams, aus einer innovativen Forschung im Bereich der Nanotransportsysteme Medikamente zu entwickeln und zu den Patienten zu bringen. Um dieses Ziel zu erreichen, arbeiten erfahrene Unternehmer und Manager Seite an Seite mit Universitätsabgängern und jungen Talenten. Nur die gemeinsame Anstrengung von Mitarbeitenden, Investoren, Ärzten und auch Patienten wird es schlussendlich möglich machen, den Weg bis zu einem verschreibungspflichtigen Medikament zu meistern.
Online-Event:
Aufzeichnung vom 10. Mai 2021
Podiumsdiskussion
live aus der NanoFactory
mit
Dr. Peter Halbherr, Verwaltungsratspräsident
Dr. Stefan Halbherr, Leiter Forschung & Entwicklung
Dr. Jonas Zeller, CFO
moderiert von
Stephan Klapproth
Um in den Vollbildmodus zu wechseln, klicken Sie unten rechts im Video auf das Icon.
Bleiben Sie auch in Zukunft informiert – mit unserem Newsletter
Innovation in Service of Patients
InnoMedica is a Swiss pharmaceutical company specialized in drug development with innovative nano transport systems that improve patient therapy. With InnoMedica’s nanocarriers, pharmaceutical agents circulate in the bloodstream for longer and are released at the designated location in the body with precision. InnoMedica thereby addresses the challenge of an efficient biodistribution of active agents in the human body, simultaneously leading to improved efficacy and reduced side effects. First applications in oncology, neurology, and virology demonstrate the impressive versatility of this nanotechnology. Translation risks in InnoMedica’s drugs are unusually low because InnoMedica does not develop new active stubstances, but instead equips clinically established medicines with a biological autopilot. At InnoMedica, experienced entrepreneurs and researchers work together in order to bring these drugs to patients as expediently as possible.
Our Products
Delivery system with precise focus
The patent-protected drug-delivery system can be combined with a multitude of medical agents and fine-tuned according to specific requirements. This versatility enables its use in a multitude of applications.
The Talidox nanocarrier encapsulates the approved and established, highly effective active substance Doxorubicin thereby preventing severe and irreversible side effects of the chemotherapy. A substantive improvement of the benefit/side-effect profile.
Therapy with Talineuren regenerates neural damages. First clinical trials with the drug are planned for patients with Parkinson’s Disease, ALS, or other neurodegenerative diseases. Furthermore, application for the treatment of neurological symptoms in Covid-19 patients is in preparation.
InnoMedica’s fully biological Covid-19 vaccine uses the nanocarrier as its carrier substance and is structured as a protein-subunit vaccine. This promises immunisation at good tolerability.
All pipeline products are based on InnoMedica’s medicinal nanocarrier transport system. They aim to improve the distribution of the active agents in the patient’s body. Established substances are encapsulated by the nanocarrier, equipped with a biological autopilot, and released at the desired tissue in the body.
Our Focus
Efficient Therapies with Fewer Side-Effects
In developing its medicines, InnoMedica focusses on the patient and his/her wish for improved health and quality of life. This means prioritizing patient benefits, as well as the real-world applicability of new drugs. Improved patient benefits primarily depend on an increase in therapeutic efficacy and a decrease in side effects. In order to reduce time to approval, InnoMedica builds its medicines on approved, best-in-class active substances.
28
patients treated with Talidox
45
employees are working on InnoMedica’s vision
950
shareholders are
invested in InnoMedica
45
Mio. CHF raised
Statements
Statements on Our Work
-
PD Dr. Michael Schüpbach
Vice President, Swiss Movement Disorder Society“Treatment with GM1 has already shown positive results in initial studies in patients with Parkinson's disease. Talineuren®, the liposomal formulation of GM1, is a promising substance whose therapeutic potential we now want to test in a clinical trial. Orphan drug status is a significant step for Talineuren® towards rapid market approval.”
-
Prof. Dr. Beat Thürlimann
St. Gallen Breast Cancer Center“The successfully completed Phase I study lays the foundation for the further development of Talidox®, which will take place internationally at renowned breast cancer centers. We expect this to lead to successful further development of the drug in breast cancer. The currently favored first line therapy for breast cancer is weekly infusions of paclitaxel (e.g. Taxol). Talidox® has the potential to become the new standard in breast cancer chemotherapies.»
-
“The main requirement for obtaining a market approval for a formulation such as Talidox®, is a safety study in humans.”
Prof. Dr. Matthias G. Wacker
Department of Pharmacy, Faculty of Science, National University of Singapore. Consultant for US Pharmacopeia (USP) and National Formulary (NF) -
Swissmedic categorizes Talidox as known substance with innovation
“Thus, the efficacy is basically considered to be given and the manufacturer only has to show to what extent the changes in the drug affect the therapeutic performance.”
Swissmedic categorizes Talidox as known substance with innovation
